2seventy bio Inc. (TSVT): Price and Financial Metrics
TSVT Price/Volume Stats
| Current price | $4.26 | 52-week high | $12.69 |
| Prev. close | $4.29 | 52-week low | $1.53 |
| Day low | $4.14 | Volume | 311,500 |
| Day high | $4.38 | Avg. volume | 1,380,578 |
| 50-day MA | $5.05 | Dividend yield | N/A |
| 200-day MA | $4.59 | Market Cap | 218.58M |
TSVT Stock Price Chart Interactive Chart >
2seventy bio Inc. (TSVT) Company Bio
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Latest TSVT News From Around the Web
Below are the latest news stories about 2SEVENTY BIO INC that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3PRINCETON, N.J., & CAMBRIDGE, Mass., December 12, 2023--Abecma Delivers Sustained Progression-Free Survival Vs. Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma.... |
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)CAMBRIDGE, Mass., December 11, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. |
2seventy bio Reiterates Commitment to Maximizing Shareholder ValueCAMBRIDGE, Mass., December 06, 2023--2seventy bio, Inc. (NASDAQ: TSVT), ("2seventy" or "the Company"), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: |
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaPRINCETON, N.J. & CAMBRIDGE, Mass., November 20, 2023--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel).... |
3 Biotech Stocks With Key Catalysts Coming in DecemberSome of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. |
TSVT Price Returns
| 1-mo | -20.37% |
| 3-mo | 32.30% |
| 6-mo | 88.50% |
| 1-year | -55.21% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -0.23% |
| 2023 | -54.43% |
| 2022 | -63.44% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...